DIACARTA

Fully-Human IgG Monoclonal Antibodies as Isotype Controls

Highlights

- Distinguishing antibody target-specific effects from backbone effects in studies.
- Low-background isotype controls for antibody characterization, such as antigen-binding affinity.
- Peer-review publication-proven negative controls for your drug discovery research.

Introduction

Characterizing target-specific effects of antibodies of interest is critical for drug discovery. Nonspecific effects initiated by the antibody Fc backbone complicate interpreting in vitro and preclinical results for antibody drug candidates (fully-human, humanized, or chimeric). A reliable isotype control is essential to qualify an antibody candidate for downstream drug development.

DiaCarta's Offerings

DiaCarta offers a collection of fully-human monoclonal antibodies for use as negative controls in vitro and for animal studies. Publications have shown that these products have been successfully used as negative controls.

Ordering information

Product Name and Description	Pack Size and Catalog Number
Human IgG1 Fully-Human IgG1 Isotype Control (Preclinical-grade)	1 mg: DC-09-0001 5 mg: DC-09-0002
Human IgG2 Fully-Human IgG2 Isotype Control (Preclinical-grade)	Custom order only with minimum 20 mg: DC-09-0003
Human IgG3 Fully-Human IgG3 Isotype Control (Preclinical-grade)	Custom order only with minimum 20 mg: DC-09-0004
Human IgG4 Fully-Human IgG4 Isotype Control (Preclinical-grade)	1 mg: DC-09-0005 5 mg: DC-09-0006

Seleted Cited Publications

- ACR Open Rheumatology Vol. 2, No. 6, June 2020, pp 344–356 DOI 10.1002/acr2.11127.
- Cell Reports 31, 107494 April 14, 2020 https://doi.org/10.1016/j.celrep.2020.03.058.
- PLoS ONE 17(3): e0265534. 2002. https://doi.org/10.1371/journal. pone.0265534.
- MABS 2018, VOL. 10, NO. 7, 1111–1130 https://doi.org/10.1080/19420862.2018.1505464.
- J. Exp. Med. 2019 Vol. 216 No. 7 1525–1541. https://doi.org/10.1084/jem.20182359.
- JCI Insight. 2022;7(5):e151624. https://doi.org/10.1172/jci.insight.151624.